# Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography

> **NCT02139371** · EARLY_PHASE1 · COMPLETED · sponsor: **Rigshospitalet, Denmark** · enrollment: 10 (actual)

## Conditions studied

- Breast Cancer
- Prostate Cancer
- Urinary Bladder Cancer

## Interventions

- **OTHER:** Injection of 64Cu-DOTA-AE105

## Key facts

- **NCT ID:** NCT02139371
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2014-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02139371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02139371, "Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02139371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*